{
    "clinical_study": {
        "@rank": "141185", 
        "arm_group": {
            "arm_group_label": "alisertib", 
            "arm_group_type": "Experimental", 
            "description": "Timeframe: 21 days"
        }, 
        "brief_summary": {
            "textblock": "Safety, tolerability and PK of concomitant esomeprazole and rifampin, and QT study on single\n      and multiple-doses of alisertib"
        }, 
        "brief_title": "Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumors", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients 18 years or older\n\n          -  Histologically or cytologically confirmed metastatic and/or advanced solid tumors or\n             lymphomas\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          -  Expected survival longer than 3 months from enrollment in the study\n\n          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2\n             effective methods of contraception or agree to abstain from heterosexual intercourse\n\n          -  Male patients who agree to practice effective barrier contraception or agree to\n             abstain from heterosexual intercourse\n\n        Exclusion Criteria:\n\n          -  Treatment with any anticancer therapy or any investigational agents within 4 weeks\n             before the first dose of alisertib\n\n             -      Known hypersensitivity or intolerance to rifampin (for patients considered for\n             the rifampin DDI group) or to esomeprazole (for patients considered for the\n             esomeprazole DDI group)\n\n          -  Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib,\n             and known GI abnormality or GI procedure that could interfere with or modify the oral\n             absorption or tolerance of alisertib\n\n          -  Patients requiring treatment with clinically significant enzyme inducers within 14\n             days before the first dose of alisertib and/or requiring the use of these medications\n             during the study\n\n          -  A medical condition requiring use of pancreatic enzymes; or daily, chronic, or\n             regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists\n\n          -  Patients requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose\n             anticoagulation to maintain patency of venous access devices).\n\n          -  Any cardiovascular condition\n\n          -  Female patients who are lactating or have a positive serum pregnancy test\n\n          -  Major surgery within the 14 days preceding the first dose of alisertib\n\n             -      Life-threatening or uncontrolled medical illness unrelated to cancer\n\n          -  Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease\n\n          -  Autologous stem cell transplant within 3 months\n\n          -  Prior allogeneic bone marrow or other organ transplantation\n\n             -      Other severe acute or chronic medical or psychiatric condition\n\n          -  Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface\n             antigen-positive status, or known or suspected active hepatitis C infection\n\n        Please note there are additional inclusion and exclusion criteria.  The study center will\n        determine if you meet all of the criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844583", 
            "org_study_id": "C14015"
        }, 
        "intervention": [
            {
                "arm_group_label": "alisertib", 
                "intervention_name": "alisertib", 
                "intervention_type": "Drug", 
                "other_name": "MLN8237"
            }, 
            {
                "arm_group_label": "alisertib", 
                "intervention_name": "esomeprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "alisertib", 
                "intervention_name": "rifampin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rifampin", 
                "Omeprazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Manish Patel"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "A. Lockhart"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shubham Pant"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Oklahoma University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Todd Bauer"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John Nemunaitis"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Mary Crowley Medical Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John Sarantopoulos"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229-3271"
                    }, 
                    "name": "Institute for Drug Devt Cancer Therapy & Research Ctr"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "Millennium Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Estimation of effect of esomeprazole on alisertib pharmacokinetics.", 
                "measure": "alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of esomeprazole", 
                "safety_issue": "No", 
                "time_frame": "Cycle 2, Day 8 and Cycle 1, Day 1"
            }, 
            {
                "description": "Estimation of effect of rifampin on alisertib pharmacokinetics.", 
                "measure": "alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of rifampin", 
                "safety_issue": "No", 
                "time_frame": "Cycle 2, Day 8 and Cycle 1, Day 1"
            }, 
            {
                "description": "Estimation of effect of alisertib on the ECG QTc interval by 12-lead Holter monitoring.", 
                "measure": "Change in QTc following single and multiple dose administration of alisertib", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Days -1, 1, 10"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessment of steady-state alisertib pharmacokinetics", 
                "measure": "alisertib steady-state PK parameters (AUC and Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1, Day 10"
            }, 
            {
                "description": "Adverse events (AEs), serious adverse events (SAEs), assessments of clinical and laboratory values, and vital sign measurements", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of the informed consent form through 30 days after the last dose of study drug"
            }, 
            {
                "description": "Estimation of effect of alisertib on ECG intervals by 12-lead Holter monitoring", 
                "measure": "Changes in ECG intervals following single and multiple dose administration of alisertib", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1, Days -1, 1, 10"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}